Detalhe da pesquisa
1.
Amino acid sequence homology of monoclonal serum free light chain dimers and tissue deposited light chains in AL amyloidosis: a pilot study.
Clin Chem Lab Med
; 62(3): 464-471, 2024 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37747270
2.
Amyloid Typing in Cardiac Amyloidosis Using Western Blotting.
Isr Med Assoc J
; 26(3): 149-156, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38493325
3.
Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study.
Br J Haematol
; 200(1): 45-53, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36205375
4.
Diagnostic Challenges and Solutions in Systemic Amyloidosis.
Int J Mol Sci
; 24(5)2023 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36902083
5.
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.
Haematologica
; 107(10): 2408-2417, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35354247
6.
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
Br J Haematol
; 192(5): 869-878, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33216361
7.
Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review.
Eur J Haematol
; 106(2): 184-195, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33090552
8.
Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Ann Hematol
; 99(6): 1273-1281, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32193630
9.
How I treat cryoglobulinemia.
Blood
; 129(3): 289-298, 2017 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-27799164
10.
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
N Engl J Med
; 373(7): 621-31, 2015 Aug 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-26035255
11.
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.
Haematologica
; 103(12): 2088-2096, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30237262
12.
Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi-center retrospective study.
Am J Hematol
; 93(6): 810-815, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29603773
13.
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.
Br J Haematol
; 178(6): 896-905, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28677826
14.
Bone mineral density utilization in patients with newly diagnosed multiple myeloma.
Hematol Oncol
; 35(4): 703-710, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27329574
15.
Efficacy and safety of autologous hematopoietic cell transplantation in elderly patients with multiple myeloma: a retrospective national multi-site cohort study.
Ann Hematol
; 96(2): 271-278, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28039512
16.
Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
Br J Haematol
; 172(1): 89-96, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26567759
17.
A practical review on carfilzomib in multiple myeloma.
Eur J Haematol
; 96(6): 564-77, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-26893241
18.
Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment.
Eur J Haematol
; 96(2): 136-43, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25827161
19.
Phase I study of the heparanase inhibitor roneparstat: an innovative approach for ultiple myeloma therapy.
Haematologica
; 103(10): e469-e472, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29700168
20.
Effect of HPSE and HPSE2 SNPs on the Risk of Developing Primary Paraskeletal Multiple Myeloma.
Cells
; 12(6)2023 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36980254